You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
昊海生物科技(06826.HK)年度歸母淨利上升53.1%至3.52億元 末期息0.7元
格隆匯 03-29 07:26

格隆匯3月29日丨昊海生物科技(06826.HK)發佈2021年全年業績公吿,報吿期內,集團實現營業收入約為人民幣17.501億元,同比增幅約為32.14%。報吿期內,集團持續加大研究與開發投入,着重擴充眼科和醫美創新產品線,報吿期內發生的研發費用約為人民幣1.676億元,同比增幅為32.51%。報吿期內,研發費用佔集團營業收入比重達到9.58%。報吿期內,集團歸屬於上市公司股東的淨利潤及歸屬於上市公司股東的扣除非經常性損益的淨利潤分約為人民幣3.522億元和人民幣3.28億元,較上年度分別上升53.10%和58.88%。基本每股盈利人民幣2元,董事會建議派發年度末期股息為每股人民幣0.7元(含税)。

報吿期內,隨着國內疫情得到有效控制,疫情對於集團經營活動的影響逐漸減弱,集團各項業務均全面恢復,各產品線的銷售收入均較2020年實現顯著增長。報吿期內,集團整體毛利率為71.98%,較2020年的74.78%有所下降,主要原因為,一方面,集團根據相關會計準則規定,對於非同一控制下企業合併中所取得的歐華美科及其附屬公司的賬面存貨,在股權收購日以可銷售價格作為其公允價值重新計量,並在相關存貨實現銷售時以相應公允價值結轉當期營業成本,使得集團合併報表中對於該等存貨的銷售毛利率為零,將報吿期內的整體毛利率拉低了約1.26%;另一方面,集團眼科人工晶狀體產品部分型號在實施帶量採購的區域銷售價格有所下降,此外,集團穩步下調了玻尿酸產品的銷售價格,以突出其“國民玻尿酸”的產品定位。集團的人工晶狀體及玻尿酸產品線均擁有豐富的產品佈局,部分中低端產品價格下調對毛利率產生了階段性影響,集團將通過努力提升中高端及高端產品的銷售佔比,以穩定整體毛利率。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account